TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37185640

Group type: EXPERIMENTAL
Intervention: Self-report diaries over 16 weeks
Number of subjects: 12
Study: 37185649

Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary follow-up (nurse-based and pharmacist-based) for 2 years
Number of subjects: 1720

Group type: COMPARATOR
Intervention: Usual follow-up
Number of subjects: 1720
Study: 37185873

Group type: EXPERIMENTAL
Intervention: Daunorubicin (90 mg/m²)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥30 kg/m²)
Number of subjects: 1088
Study: 37185903

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (sending glucose readings via smartphone application and monthly video calls)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care (routine monthly on-site visits)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 106
Study: 37185921

Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 155
Study: 37185961

Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy (maintenance)
Number of subjects: 14836

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) with chemotherapy (maintenance)
Number of subjects: 14836

Group type: EXPERIMENTAL
Intervention: TKIs with chemotherapy (maintenance)
Number of subjects: 14836

Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy (maintenance) in platinum-sensitive EOC
Number of subjects: 14836

Group type: EXPERIMENTAL
Intervention: TKIs with chemotherapy in platinum-sensitive EOC
Number of subjects: 14836

Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy (maintenance) in platinum-resistant EOC
Number of subjects: 14836

Group type: EXPERIMENTAL
Intervention: TKIs with chemotherapy in platinum-resistant EOC
Number of subjects: 14836
Study: 37186034

Group type: EXPERIMENTAL
Intervention: Hippotherapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (physiotherapy with balance exercises only)
Number of subjects: 34
Study: 37186063

Group type: EXPERIMENTAL
Intervention: Binimetinib 45 mg orally twice daily (bid) with Hydroxychloroquine 400 mg orally bid
Number of subjects: 9
Study: 37186070

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 37186094

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion at incremental rates up to 1.0 μg/kg/min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Discontinuation of phenylephrine infusion
Number of subjects: 30
Study: 37186265

Group type: EXPERIMENTAL
Intervention: Intranasal GnRH-agonist
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vaginal progesterone
Number of subjects: 150
Study: 37186316

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe depressive symptoms (MSD, CESD-10 ≥10)
Number of subjects: 4153

Group type: EXPERIMENTAL
Intervention: Mild-to-severe depressive symptoms (Mild-SD, CESD-10 ≥5)
Number of subjects: 4153

Group type: EXPERIMENTAL
Intervention: Low social support (MOS-SSS <72)
Number of subjects: 4153
Study: 37186357

Group type: EXPERIMENTAL
Intervention: Transabdominal electrical stimulation by interferential therapy (IFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 0
Study: 37186574

Group type: EXPERIMENTAL
Intervention: App-based exercise program
Number of subjects: 43
Study: 37186577

Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 21320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21320
Study: 37186584

Group type: EXPERIMENTAL
Intervention: MAPSS-DM intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 66
Study: 37186772

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training during a standardized pulmonary rehabilitation program (5 days a week for 4 weeks)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training during a standardized pulmonary rehabilitation program
Number of subjects: 73
Study: 37186949

Group type: EXPERIMENTAL
Intervention: Combined weight loss and exercise intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased dSL content in primary human myotubes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dSL levels in muscle
Number of subjects: 0
Study: 37187198

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (3 mg/m2)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Standard chemotherapy (idarubicin, cytarabine, etoposide, ATRA)
Number of subjects: 588
Study: 37187201

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy
Number of subjects: 80
Study: 37187219

Group type: EXPERIMENTAL
Intervention: 5-session PCST protocol
Number of subjects: 327

Group type: COMPARATOR
Intervention: 1-session PCST protocol
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: 1-session PCST followed by 5 maintenance telephone calls for responders or 5 sessions of PCST for nonresponders
Number of subjects: 327
Study: 37187329

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting left ventricular ejection fraction (LVEF) ≤40%
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting infarction size (IS) ≥20% on the LV mass
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting microvascular dysfunction
Number of subjects: 584
Study: 37187722

Group type: EXPERIMENTAL
Intervention: Day Surgery (DS) in selected children undergoing R-RALP
Number of subjects: 32
Study: 37187863

Group type: EXPERIMENTAL
Intervention: e-CBT (online cognitive behavioral therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person CBT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: e-CBT
Number of subjects: 0
Study: 37187878

Group type: EXPERIMENTAL
Intervention: Leucine-enriched amino acid supplementation (6 g per day for 12 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Leucine-enriched amino acid supplementation and resistance exercise
Number of subjects: 22
Study: 37188177

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS) testing and medical interpretation by a multidisciplinary molecular advisory board (MAB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient empowerment program including educational workshops and videos about mBC and precision medicine
Number of subjects: 0
Study: 37188309

Group type: EXPERIMENTAL
Intervention: Strength training (twice a week for 8 weeks, 50 min each session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 37188389

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 280

Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 280
Study: 37188468

Group type: EXPERIMENTAL
Intervention: Caffeine 1.5 mg/kg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Dextrose 5% in water placebo
Number of subjects: 250
Study: 37188469

Group type: EXPERIMENTAL
Intervention: Culturally competent intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37188668

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks
Number of subjects: 40
Study: 37188782

Group type: EXPERIMENTAL
Intervention: GD2-CAR.15 NKTs
Number of subjects: 12
Study: 37188783

Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous anti-PD-1 antibody pembrolizumab
Number of subjects: 49
Study: 37188890

Group type: EXPERIMENTAL
Intervention: Monopolar tungsten needle electrodes and PTFE-coated spatula electrodes
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional dissection with sharp instruments and coagulation with uncoated steel electrodes
Number of subjects: 132
Study: 37188895

Group type: EXPERIMENTAL
Intervention: napabucasin (480 mg/day) plus sorafenib (800 mg/day)
Number of subjects: 6
Study: 37189057

Group type: EXPERIMENTAL
Intervention: Betadine-coated gastrostomy tube
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (non-Betadine-coated gastrostomy tube)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Delta CRP
Number of subjects: 50
Study: 37189075

Group type: EXPERIMENTAL
Intervention: First-line pembrolizumab plus chemotherapy in treatment-naïve LCC (n=27)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: First-line pembrolizumab plus chemotherapy in treatment-naïve LCNEC (n=10)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subsequent-line pembrolizumab with or without chemotherapy in pre-treated LCC (n=23)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subsequent-line pembrolizumab with or without chemotherapy in pre-treated LCNEC (n=23)
Number of subjects: 60
Study: 37189085

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (methylprednisolone intravenously for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal treatment
Number of subjects: 0
Study: 37189091

Group type: EXPERIMENTAL
Intervention: AUEC enrollment
Number of subjects: 533

Group type: COMPARATOR
Intervention: MC enrollment
Number of subjects: 533
Study: 37189100

Group type: EXPERIMENTAL
Intervention: Winter hiking intervention with free access to a regional winter hiking challenge and winter traction cleats in the second study.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Winter hiking intervention (without traction cleats in the first study).
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 104
Study: 37189128

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Snuff use
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1279
Study: 37189149

Group type: EXPERIMENTAL
Intervention: PRISM-AC intervention (skills-based training program with four 30-60 min sessions, family meeting, smartphone app, and advance care planning module)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual, non-directive, supportive care without PRISM-AC (control arm)
Number of subjects: 144
Study: 37189151

Group type: EXPERIMENTAL
Intervention: miR-200-sign-up
Number of subjects: 107

Group type: COMPARATOR
Intervention: miR-200-sign-down
Number of subjects: 107
Study: 37189166

Group type: EXPERIMENTAL
Intervention: Hospital-level education intervention designed to reduce anastomotic leak, including online learning, patient risk stratification, and an in-theatre checklist.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 0
Study: 37189171

Group type: EXPERIMENTAL
Intervention: Novel medication alerts encouraging collaboration between prescribers and expert pharmacists in anticoagulation clinics.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alerts for newly prescribed inappropriate DOACs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Existing prescription notifications for inappropriate DOACs.
Number of subjects: 0
Study: 37189173

Group type: EXPERIMENTAL
Intervention: Cognitive assessment using self-rated questionnaires (Perceived Deficits Questionnaire, Hospital Anxiety and Depression Scale, Davidson Trauma Scale) and comprehensive neuropsychological evaluation.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-rated questionnaires for emotional state assessment.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Perceived cognitive deficit measure.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Demographic and clinical data analysis.
Number of subjects: 80
Study: 37189190

Group type: EXPERIMENTAL
Intervention: Parent Intervention (PI)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Summer Camp (SCV)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combination of Summer Camp and Parent Intervention (SCV+PI)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Summer Programming (SCV and PI)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Overall Efficacy
Number of subjects: 89
Study: 37189224

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Brachial Plexus Block (BP)
Number of subjects: 76
Study: 37189240

Group type: EXPERIMENTAL
Intervention: Probiotics and nutritional supplements
Number of subjects: 0
Study: 37190160

Group type: EXPERIMENTAL
Intervention: Dietary rice bran
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control AIN93M
Number of subjects: 40
Study: 37190238

Group type: EXPERIMENTAL
Intervention: Nursing calls focused on advance care planning (ACP), symptom management, and care coordination
Number of subjects: 218
Study: 37190598

Group type: EXPERIMENTAL
Intervention: TTFields combined with TMZ
Number of subjects: 1

Group type: COMPARATOR
Intervention: TMZ alone (implied control)
Number of subjects: 1
Study: 37190665

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus upper limb robot-assisted therapy (UL-RAT) using an exoskeleton robotic system (Armeo)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 84
Study: 37190883

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone-marrow-derived mononuclear cells with Impella CP device support
Number of subjects: 20
Study: 37190970

Group type: EXPERIMENTAL
Intervention: Digital solution (Noona)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Phone calls
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both modalities
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Digital solution
Number of subjects: 142
Study: 37191077

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 0
Study: 37191154

Group type: EXPERIMENTAL
Intervention: High-intensity care (HIC) strategy of guideline-directed medical therapies (GDMT) up-titration
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1078
Study: 37191188

Group type: EXPERIMENTAL
Intervention: Arginine methylation inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37191339

Group type: EXPERIMENTAL
Intervention: 10 h of SOP training
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216
Study: 37191612

Group type: EXPERIMENTAL
Intervention: Burst SCS
Number of subjects: 29

Group type: COMPARATOR
Intervention: L2 DRGS
Number of subjects: 29
Study: 37191681

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) using 18F-PFPN
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 76
Study: 37191697

Group type: EXPERIMENTAL
Intervention: Active tDCS (30 min at 2 mA, anode over F3, cathode over F4) for 6 weeks, 5 sessions/week
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham tDCS (resembled active tDCS but without intermittent stimulation)
Number of subjects: 11
Study: 37191738

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 37191995

Group type: COMPARATOR
Intervention: Sit-to-stand desk
Number of subjects: 66

Group type: COMPARATOR
Intervention: Treadmill desk
Number of subjects: 66
Study: 37192040

Group type: EXPERIMENTAL
Intervention: BI 655064 120 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: BI 655064 180 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: BI 655064 240 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 37192167

Group type: EXPERIMENTAL
Intervention: Sex chromosome aneuploidies (XX, XXX, XY, XXY, XYY, XXYY)
Number of subjects: 197
Study: 37192176

Group type: EXPERIMENTAL
Intervention: TAU + e-CBTi
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAU + trazodone
Number of subjects: 60
Study: 37192190

Group type: EXPERIMENTAL
Intervention: Community Mobilization and Community Incentivization (CoMIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive inclusive community engagement and demand creation strategies tied to conditioned short term tangible incentives
Number of subjects: 0
Study: 37192204

Group type: EXPERIMENTAL
Intervention: Chronic postsurgical pain at 3 months after surgery
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Chronic postsurgical pain at 6 months after surgery
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Chronic postsurgical pain at 12 months after surgery
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Neuropathic phenotype pain at 3 months
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Neuropathic phenotype pain at 6 months
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Neuropathic phenotype pain at 12 months
Number of subjects: 767
Study: 37192282

Group type: EXPERIMENTAL
Intervention: Healthy behavior text messaging (yes)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Prompted self-measured blood pressure monitoring and feedback (weekly)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Prompted self-measured blood pressure monitoring and feedback (daily)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Facilitated primary care provider appointment scheduling and transportation (yes)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Healthy behavior text messaging (no)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Prompted self-measured blood pressure monitoring and feedback (no)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Facilitated primary care provider appointment scheduling and transportation (no)
Number of subjects: 488
Study: 37192288

Group type: EXPERIMENTAL
Intervention: Cardiac scale measurements (daily)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Composite index derived from noninvasive hemodynamic biomarkers
Number of subjects: 300

Group type: COMPARATOR
Intervention: Simple weight-based rule-of-thumb algorithms
Number of subjects: 300
Study: 37192308

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 200
Study: 37192310

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Medical management (Medical-Mod)
Number of subjects: 706
Study: 37192425

Group type: EXPERIMENTAL
Intervention: Opioid-sparing multimodal analgesia (ketorolac, orphenadrine, and gabapentin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opioid-based regimen
Number of subjects: 0
Study: 37192437

Group type: EXPERIMENTAL
Intervention: Pirtobrutinib monotherapy
Number of subjects: 90
Study: 37192443

Group type: EXPERIMENTAL
Intervention: Phosphodiesterase-4 Inhibition
Number of subjects: 0
Study: 37192445

Group type: EXPERIMENTAL
Intervention: Noninvasive respiratory support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 37192642

Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 37192697

Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable polymer Sirolimus-eluting stents (BP-SES)
Number of subjects: 3397

Group type: COMPARATOR
Intervention: Thin-strut durable polymer Everolimus-eluting stents (DP-EES)
Number of subjects: 3397
Study: 37192698

Group type: EXPERIMENTAL
Intervention: AI image analysis report (EchoGo Pro)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Current practice (control group)
Number of subjects: 2500
Study: 37192729

Group type: EXPERIMENTAL
Intervention: HuSC1-39 (anti-TF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-targeting anti-TF&TGFβR fusion protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anti-TF or TF-knockout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TF-high TNBC cells treated with anti-TF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 37192741

Group type: EXPERIMENTAL
Intervention: Nomogram developed using levels of 45 cytokines (CX3CL1, GZMB, IL4, IL6, PDGFAA) on days 1-2 after CAR-T cell infusion.
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Nomogram validation in external cohorts (MM).
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Nomogram validation in external cohorts (ALL/NHL).
Number of subjects: 214
Study: 37192754

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion to increase mean arterial blood pressure (MAP) by a maximum of 30 mmHg to an absolute level of no more than 130 mmHg.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion to increase MAP.
Number of subjects: 36
Study: 37192785

Group type: EXPERIMENTAL
Intervention: Ropivacaine via bilateral cESP catheters
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study: 37192994

Group type: EXPERIMENTAL
Intervention: AG-920 (articaine ophthalmic solution)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 37193282

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 53

Group type: COMPARATOR
Intervention: Wake
Number of subjects: 53
Study: 37193393

Group type: EXPERIMENTAL
Intervention: 5-h TIB during sleep restriction
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 6.5-h TIB during sleep restriction
Number of subjects: 57

Group type: COMPARATOR
Intervention: 9-h TIB during baseline and recovery nights
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Drift diffusion modelling (DDM) measures
Number of subjects: 57
Study: 37193586

Group type: EXPERIMENTAL
Intervention: Reintubated infants after extubation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Criteria used for reintubation in clinical practice
Number of subjects: 55
Study: 37193776

Group type: EXPERIMENTAL
Intervention: EPI (ExoDx Prostate test)
Number of subjects: 1049

Group type: COMPARATOR
Intervention: SOC (Standard of Care)
Number of subjects: 1049
Study: 37194008

Group type: EXPERIMENTAL
Intervention: Implementation of IPC measures (poor, moderate, thorough)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thorough implementation of IPC measures
Number of subjects: 0